Oligodendroglioma
MONDO:0016695A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres. It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)
Also known as: oligodendroglial neoplasm, oligodendroglial tumor, oligodendroglial tumour, WHO grade II oligodendroglial neoplasm, WHO grade II oligodendroglial tumor, WHO grade II oligodendroglial tumour, oligodendroglioma, well differentiated oligodendroglial tumor
2878 clinical trials for this condition and its sub-types, 62 tagged with Oligodendroglioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Oligodendroglioma
-
Adult oligodendroglioma 3 trials
-
Childhood oligodendroglioma 1 trial
-
Brain oligodendroglioma 0 trials
1 sub-type
- Corpus callosum oligodendroglioma 0 trials
-
Spinal cord oligodendroglioma 0 trials
-
Oral Brain-Penetrating drug tested against aggressive IDH1-Mutant gliomas
Disease control Not yet recruitingResearchers are testing an oral drug called safusidenib in adults newly diagnosed with IDH1-mutant grade 3 oligodendroglioma or astrocytoma, two types of brain tumor. Safusidenib is designed to cross into the brain and block the mutated IDH1 enzyme that drives these tumors. All 2…
Phase 2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Radioactive tiles target brain tumors in frail patients
Disease control Not yet recruitingResearchers are testing whether GammaTile, a collagen tile embedded with radioactive cesium-131 seeds, can be safely placed in the brain after surgery for malignant glioma. The trial enrolls elderly or frail patients with newly diagnosed or recurrent tumors. The main goals are to…
Phase 2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for brain tumor patients when standard drug fails
Disease control Not yet recruitingThis study tests an experimental drug called safusidenib in people with a slow-growing brain tumor (IDH1-mutant glioma) whose tumor got worse while on the standard drug vorasidenib. Up to 40 participants take safusidenib pills twice daily to see if the tumor shrinks or stops grow…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Targeted pill aims to stall a common brain Tumor's growth
Disease control Not yet recruitingThis study tests whether the experimental drug safusidenib can slow or stop the growth of a type of slow-growing brain tumor called grade 2 glioma that has a specific genetic change (IDH1 mutation). Participants have had surgery but no other treatments like chemotherapy or radiat…
Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New group program aims to boost Well-Being in brain cancer patients
Symptom relief Not yet recruitingThis study tests a new group self-management program for adults with brain cancer. The goal is to see if the program is practical and helps improve mental health and quality of life more than standard care. Researchers will compare changes in well-being between the group program …
Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Brain tumor study aims to clear up scans by shifting chemo timing
Knowledge-focused Not yet recruitingThis study tests giving chemotherapy before radiation for people with high-grade gliomas, a type of aggressive brain tumor. The goal is to see if this approach works well and makes MRI scans easier to read, since radiation can change how the brain looks. About 70 adults aged 18-8…
Phase 2 • Sponsor: The Cooper Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC